randomised-double-blind

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 79/100

   Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

   ✓ Peer-reviewed alzhub usefulness score 79 out of 100. EBioMedicine · 2023-06-29 · Treatments

   Between 7 December 2015 and 28 August 2018, 43 participants were randomised.

   • Clinical Trials
   • Side Effects
   • Treatments
2. 60/100

   Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial

   ✓ Peer-reviewed alzhub usefulness score 60 out of 100. BMJ open · 2020-02-06 · Brain scans and imaging

   After infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and can enter the brain via retrograde axonal transport.

   • Treatments
   • Clinical Trials
   • Brain Scans
3. 77/100

   Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial

   ✓ Peer-reviewed alzhub usefulness score 77 out of 100. The Lancet. Neurology · 2013-01-02 · Treatments

   Of 100 patients screened, 81 were randomly assigned to receive memantine (39 patients) or placebo (42 patients).

   • Clinical Trials
   • Treatments
   • Other Dementias
4. 78/100

   Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial

   ✓ Peer-reviewed alzhub usefulness score 78 out of 100. PloS one · 2012-05-02 · Treatments

   Memantine did not improve significant agitation in people with in moderate-to-severe AD.

   • Clinical Trials
   • Treatments
5. 77/100

   Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial

   ✓ Peer-reviewed alzhub usefulness score 77 out of 100. Lancet (London, England) · 2012-01-10 · Treatments

   After adjustment for baseline score, there were non-significant differences between groups of -4·1 (95% CI -13·1 to 4·8) in DAMES scores, -8·5 (-20·1 to 3·1) in ABS I scores, and 2·0 (-7·2 to 11·3) in ABS II scores, all in favour of controls. 10 (11%) of 88 participants in the memantine group and six (7%) of 85 controls had serious adverse events (p=0·33).

   • Treatments
   • Clinical Trials

All topic tags with their study counts